
Galectin Therapeutics Inc.: updates and filings
Price
$2.69
November 20, 2026Market cap $271M
What Ploutos Investor adds for Galectin Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Results of operationsForm8-K
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 13, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Oct 13, 2026Additional annual meeting materialFormDEFA14A
- Oct 13, 2026Annual meeting proxy statementFormDEF 14A
- Oct 2, 2026Preliminary proxy statementFormPRE 14A
- Aug 14, 2026Results of operationsForm8-K
- Aug 14, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 4, 2026Unregistered sale of sharesForm8-K
- Jun 23, 2026Regulation FD disclosureForm8-K
- May 15, 2026Results of operationsForm8-K
- May 15, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 10, 2026FilingFormEFFECT
- Apr 8, 2026Correspondence with the SECFormCORRESP
- Apr 6, 2026Letter from the SECFormUPLOAD
- Mar 31, 2026Shelf registration for future offeringsFormS-3
- Mar 31, 2026Results of operationsForm8-K
- Mar 31, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 17, 2026Officer or director changeForm8-K
- Jan 21, 2026Officer or director changeForm8-K
- Jan 12, 2026Officer or director changeForm8-K
- Jan 5, 2026Filing (amendment)Form144/A
- Dec 19, 2025Material agreement enteredForm8-K
- Dec 15, 2025Filing (amendment)Form144/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 13, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Oct 13, 2026 | DEFA14A | Additional annual meeting material | Document |
| Oct 13, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Oct 2, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Aug 14, 2026 | 8-K | Results of operations | Document |
| Aug 14, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 4, 2026 | 8-K | Unregistered sale of shares | Document |
| Jun 23, 2026 | 8-K | Regulation FD disclosure | Document |
| May 15, 2026 | 8-K | Results of operations | Document |
| May 15, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 10, 2026 | EFFECT | Filing | Document |
| Apr 8, 2026 | CORRESP | Correspondence with the SEC | Document |
| Apr 6, 2026 | UPLOAD | Letter from the SEC | Document |
| Mar 31, 2026 | S-3 | Shelf registration for future offerings | Document |
| Mar 31, 2026 | 8-K | Results of operations | Document |
| Mar 31, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 17, 2026 | 8-K | Officer or director change | Document |
| Jan 21, 2026 | 8-K | Officer or director change | Document |
| Jan 12, 2026 | 8-K | Officer or director change | Document |
| Jan 5, 2026 | 144/A | Filing (amendment) | Document |
| Dec 19, 2025 | 8-K | Material agreement entered | Document |
| Dec 15, 2025 | 144/A | Filing (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 13, 2001. Of its note and share prospectuses (424B, FWP), the newest 40 of 45.
The full analysis
What do Galectin Therapeutics's filings show?
The filings are where every one of Galectin Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.